Orchestrating the fecal microbiota transplantation: Current technological advancements and potential biomedical application

Abstract

Fecal microbiota transplantation (FMT) has been proved to be an effective treatment for gastrointestinal disorders caused due to microbial disbalance. Nowadays, this approach is being used to treat extragastrointestinal conditions like metabolic and neurological disorders, which are considered to have their provenance in microbial dysbiosis in the intestine. Even though case studies and clinical trials have demonstrated the potential of FMT in treating a variety of ailments, safety and ethical concerns must be answered before the technique is widely used to the community's overall benefit. From this perspective, it is not unexpected that techniques for altering gut microbiota may represent a form of medication whose potential has not yet been thoroughly addressed. This review intends to gather data on recent developments in FMT and its safety, constraints, and ethical considerations.

The gut microbiota and endometriosis: From pathogenesis to diagnosis and treatment

“…Fecal microbiota transplantation (FMT) refers to a standardized treatment in which the feces of healthy people, and therefore the acquired functional flora, is transplanted into the gastrointestinal tract of patients with dysbacteriosis to rebuild the gut microbiota of patients and treat disease ( Kelly et al., 2015 ; Nigam et al., 2022 ). At present, FMT has been applied for the treatment of gastrointestinal diseases, blood diseases, neuropsychiatric diseases, chronic hepatitis B, metabolic syndrome, drug-resistant bacterial infections and other diseases ( Brandt and Aroniadis, 2013 ; Kim and Gluck, 2019 ).…”